Actively Recruiting
Evaluation of JNJ-101556143 Oral Treatment in Men with Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer
Led by Janssen Research & Development, LLC · Updated on 2026-11-03
100
Participants Needed
14
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well JNJ-101556143 works in people with metastatic androgen pathway modulation-resistant prostate cancer mAPMR, a form of advanced prostate cancer that no longer responds to hormone therapy. This study aims to measure the overall response, including tumor shrinkage or disappearance, after treatment with this investigational drug. The trial is a Phase 2, open-label, multicenter, single-arm study sponsored by Janssen Research & Development, LLC. Participants will receive JNJ-101556143 orally once daily in 28-day treatment cycles. Treatment continues until the disease shows confirmed progression by imaging or clear clinical signs, or if other protocol-defined reasons require stopping. The study evaluates the drugs effects over up to 2 years and 8 months, including response duration, progression-free survival, and time to symptom progression. During the trial, participants will undergo regular assessments including imaging scans, laboratory tests, and measurements of drug levels in the blood to monitor response and safety. Researchers will track adverse events and clinical lab abnormalities throughout. The primary outcome is the overall response rate measured over nearly three years. Participants remain on study until progression or discontinuation criteria are met, with ongoing safety and disease monitoring throughout their participation.
CONDITIONS
Brief Title
A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here